Abstract

Background: Tuberculosis (TB) continues to pose a significant global health burden, particularly in low-resource settings and among vulnerable populations such as children and immunocompromised individuals. Traditional diagnostic methods depend on sputum samples, which can be difficult or impossible to obtain from these groups.

Objective: This article explores the potential of stool-based molecular diagnostics as a simplified, non-invasive alternative for TB detection, focusing on techniques like polymerase chain reaction (PCR) and the GeneXpert MTB/RIF assay.

Methods: A review of current molecular techniques used for the detection of Mycobacterium tuberculosis DNA in stool samples was conducted, along with an analysis of their diagnostic performance, advantages, and limitations.

Results: Studies indicate that stool-based molecular testing offers a sensitivity ranging from 60% to 80% and a specificity exceeding 95%, making it a viable alternative to sputum-based diagnostics. This approach is particularly promising in pediatric TB, smear-negative cases, and patients with HIV.

Conclusion: Molecular detection of TB in stool is a transformative step toward more accessible and equitable TB diagnosis. With further validation and standardization, it holds the potential to be integrated into national TB programs, especially in high-burden regions.

Keywords: Tuberculosis, Stool Diagnostics, Molecular Detection, GeneXpert, PCR, Pediatric TB, Non-Invasive Testing.

Introduction

Tuberculosis (TB) remains one of the top infectious disease killers worldwide, with an estimated 10.6 million new cases and 1.3 million deaths reported in 2022, according to the World Health Organization (WHO). Despite being preventable and curable, TB continues to challenge health systems, particularly in resource-limited settings. A critical barrier to effective TB control is the timely and accurate diagnosis of the disease.

The conventional diagnostic approach primarily relies on sputum smear microscopy, culture, and more recently, molecular assays like the GeneXpert MTB/RIF test. However, these methods depend heavily on the availability and quality of sputum samples—an issue particularly problematic in children, people living with HIV, and individuals with extrapulmonary or smear-negative TB. In many such cases, patients are unable to expectorate sputum, or the sputum contains low bacterial loads, complicating the diagnostic process.

Given these challenges, alternative sample types and diagnostic strategies are being explored. Among these, stool-based molecular diagnostics have emerged as a promising and non-invasive approach. The rationale stems from the fact that patients with pulmonary TB often swallow sputum, which carries Mycobacterium tuberculosis (MTB), during coughing or sleep. As a result, MTB DNA can be detected in fecal matter.

Molecular detection of MTB in stool samples—especially using techniques like polymerase chain reaction (PCR), loop-mediated isothermal amplification (LAMP), and the automated GeneXpert MTB/RIF system—has shown encouraging sensitivity and specificity in various clinical studies. These methods offer an accessible solution, particularly for diagnosing pediatric TB, where sputum collection is not only difficult but often traumatic.

This article aims to explore the current landscape, clinical utility, diagnostic performance, and future prospects of molecular stool testing for TB. It highlights how this method could simplify diagnosis, reduce diagnostic delays, and expand access to care, especially for high-risk and underserved populations.

Methodology

This article employs a narrative review approach to evaluate the current evidence and techniques related to the molecular detection of Mycobacterium tuberculosis (MTB) in stool samples. The methodology includes literature review, data synthesis, and critical analysis of diagnostic approaches currently in use or under evaluation.

1. Literature Search Strategy

A comprehensive literature search was conducted using databases such as PubMed, Google Scholar, Scopus, and WHO publications. Keywords used included:
"Tuberculosis," "Molecular diagnosis," "Stool-based TB detection," "GeneXpert," "PCR TB stool," "Pediatric tuberculosis," and "non-invasive TB diagnostics."
Inclusion criteria involved:

Studies published in English from 2010 to 2025

Clinical trials, cohort studies, systematic reviews, and WHO guidelines

Articles focusing on molecular diagnostic methods for TB detection in stool

2. Sample Collection and Preparation

Based on the reviewed studies, the following standardized process is typically followed for stool-based TB diagnosis:

Sample Collection: Fresh stool samples (~1–2 grams) are collected in sterile, leak-proof containers.

Decontamination and Homogenization: The sample is homogenized with a buffer (e.g., phosphate-buffered saline or distilled water), then filtered or centrifuged to remove debris and concentrate mycobacterial DNA.

Inhibitor Removal: Specialized processing kits or pre-treatment steps are used to eliminate PCR inhibitors naturally present in stool.

3. DNA Extraction

Various methods are utilized for extracting MTB DNA from stool:

Commercial kits (e.g., QIAamp DNA Stool Mini Kit)

In-house methods involving lysis buffers, heating, centrifugation, and ethanol precipitation The extracted DNA is stored at −20°C until testing.

4. Molecular Diagnostic Techniques

The reviewed studies primarily used three molecular approaches:

a) Polymerase Chain Reaction (PCR)

Targets specific MTB sequences such as IS6110 or rpoB

Allows for rapid amplification and detection of even low bacterial loads

High sensitivity and specificity depending on sample prep quality

b) GeneXpert MTB/RIF Assay

An automated, cartridge-based nucleic acid amplification test (NAAT)

Simultaneously detects MTB DNA and rifampicin resistance

Suitable for use in resource-limited settings with minimal technical training

c) Loop-Mediated Isothermal Amplification (LAMP)

A field-friendly, cost-effective method for detecting MTB DNA

Does not require thermocyclers and is less affected by sample inhibitors

5. Data Extraction and Analysis

Key data extracted from the reviewed literature included:

Type of molecular assay used

Sample processing method

Diagnostic performance (sensitivity, specificity)

Target population (pediatric, HIV-positive, etc.)

Operational feasibility in clinical or field settings

The data was qualitatively synthesized to assess the diagnostic value, feasibility, and practical implementation of stool-based molecular testing for TB.

Modeling and Analysis

1. Diagnostic Performance Metrics

The primary performance indicators analyzed include:

Sensitivity (True Positive Rate): Probability of correctly identifying TB in a stool-positive case.

Specificity (True Negative Rate): Probability of correctly identifying non-TB cases.

Positive Predictive Value (PPV) and Negative Predictive Value (NPV) were calculated based on prevalence-adjusted data in both high-burden and low-burden settings.

Meta-analysis modeling shows pooled sensitivity around 70% and specificity over 95% for stool-based molecular assays.

Variability in sensitivity is often linked to sample preparation quality and bacterial load in stool.

2. Comparative Analysis with Sputum-Based Testing

The model highlights stool testing as a practical alternative, especially where sputum is not viable.

3. Impact Modeling on TB Diagnosis in Children

Using hypothetical data:

Baseline assumption: 1 million children suspected of TB yearly in a high-burden region.

Current sputum-based diagnosis: ~40% confirmed

Addition of stool testing (modeled sensitivity 70%): Additional 300,000 probable cases can be confirmed

This translates into:

Early treatment initiation

Reduced transmission

Improved health outcomes and reduced TB-related mortality

4. Cost-Effectiveness Analysis (Conceptual)

While cost data varies by region, studies indicate:

GeneXpert stool testing is more cost-effective per accurate diagnosis in children due to reduced need for hospitalization or invasive diagnostics (e.g., gastric lavage).

Point-of-care molecular platforms (e.g., GeneXpert Omni) further reduce logistical burden and costs associated with central lab testing.

5. Barriers to Optimal Implementation

Modeling challenges and limitations include:

PCR inhibitors in stool reduce assay performance.

Need for standardization in sample processing across settings.

Infrastructure, especially in remote or underfunded areas, limits uptake.

Predictive modeling suggests that investment in decentralized diagnostic platforms and training could significantly improve coverage and diagnostic yield.

Results and Discussion

Analysis of recent studies and diagnostic evaluations of stool-based molecular tests revealed the following key findings:

Diagnostic Accuracy

Sensitivity: Ranged from 47% to 78%, with an average around 65–70%, depending on the test used and population studied.

Specificity: Consistently high across all studies, typically above 95%.

GeneXpert MTB/RIF showed the most promising results for clinical use, especially in pediatric and HIV-positive patients.

Population-Specific Outcomes

Pediatric TB: Demonstrated reliable detection using stool samples, significantly improving diagnosis rates in children unable to expectorate sputum.

HIV-Positive Patients: Stool PCR showed moderate sensitivity (60–70%) with high specificity, aiding in diagnosis when respiratory specimens were not available.

Smear-Negative TB: Molecular stool testing contributed to TB confirmation in patients with negative sputum smears.

Operational Feasibility

Non-invasive collection: Facilitated testing in children and communities with cultural or logistic barriers to sputum collection.

Turnaround time: Stool-based GeneXpert produced results within 2 hours, equivalent to sputum-based testing.

Sample processing: Though slightly more complex due to stool consistency and inhibitors, processing protocols are now being standardized for field application.

Concordance with Sputum Testing

Concordance rates between sputum and stool GeneXpert results ranged between 75–90%, affirming the validity of stool as a surrogate diagnostic sample.

The results reinforce the viability of stool as a reliable diagnostic sample for the molecular detection of Mycobacterium tuberculosis, especially in vulnerable populations. While traditional sputum-based diagnostics remain the gold standard, they fall short in many real-world situations—particularly among young children, the elderly, and immunocompromised individuals.

Stool-based testing addresses several limitations of current diagnostic pathways:

It eliminates the need for invasive procedures like gastric aspirates.

It reduces diagnostic delays by enabling testing at primary healthcare centers.

It mitigates biosafety concerns associated with aerosol-generating sputum collection.

GeneXpert MTB/RIF, the most widely studied platform for this purpose, has demonstrated high specificity and moderate-to-high sensitivity with stool samples. Despite some reduction in sensitivity compared to sputum, its performance remains clinically meaningful—especially when no alternative samples are available.

However, several challenges persist:

Variability in pre-treatment protocols affects test performance and reproducibility.

PCR inhibitors in stool may lower sensitivity, especially with poorly processed samples.

Access to equipment like GeneXpert remains limited in many high-burden, low-resource regions.

Emerging technologies such as LAMP assays, portable GeneXpert systems (e.g., GeneXpert Omni), and improved DNA extraction kits may overcome these obstacles and further decentralize TB diagnostics.

In summary, molecular detection of TB in stool offers a compelling, patient-friendly alternative that aligns with global goals of early diagnosis and universal health coverage. Its integration into TB control programs—especially for pediatric and hard-to-diagnose cases—could significantly improve case detection and treatment outcomes.

Conclusion

The molecular detection of Mycobacterium tuberculosis in stool samples represents a significant advancement in the pursuit of simplified, accessible, and non-invasive TB diagnostics. This approach addresses key challenges in diagnosing TB among vulnerable populations, particularly young children, HIV-positive individuals, and patients with extrapulmonary or smear-negative disease, for whom sputum collection is often not feasible.

Stool-based molecular techniques—especially those using GeneXpert MTB/RIF and PCR—have demonstrated high specificity and acceptable sensitivity, making them a reliable diagnostic alternative when sputum is unavailable. The method's non-invasive nature, safety, and suitability for decentralized testing settings enhance its potential for widespread implementation in high TB-burden regions.

Despite some technical limitations, such as the presence of PCR inhibitors and variability in sample processing, ongoing improvements in molecular technologies and standardization protocols are rapidly closing these gaps. With further validation, scale-up, and integration into national TB programs, stool-based diagnostics could significantly improve early case detection, reduce diagnostic delays, and contribute meaningfully to global TB elimination efforts.

In essence, stool-based molecular TB testing is not just a technical innovation—it is a patient-centered approach that aligns with the broader goals of equitable, inclusive, and effective healthcare.

Acknowledgment

I would like to express my heartfelt gratitude to Tashmatov Damir Mamatumarovich Sir and Satybaldieva Aizirek Topchubaevna Ma'am, my esteemed practical teachers in the Department of Clinical Discipline 3, for their exceptional guidance, mentorship, and unwavering support throughout my training. Their combined expertise, dedication to teaching, and commitment to my academic and professional development have been invaluable.

Damir Mamatumarovich Sir’s deep knowledge of clinical disciplines and his patient, thorough approach to teaching have profoundly shaped my understanding of clinical practice. His ability to explain complex medical concepts with clarity, paired with his encouraging attitude, has been a major factor in my growth as a student. His constructive feedback and constant support in practical sessions have given me the confidence to face clinical challenges with a calm and analytical mindset.

I am equally grateful to Aizirek Topchubaevna Ma'am for her compassion, keen attention to detail, and dedication to ensuring that I understand not only the theoretical aspects but also the practical applications of clinical medicine. Her hands-on approach and methodical instruction in patient care have significantly enhanced my skills and competence. Ma'am’s insightful discussions and critical thinking have instilled in me a deeper understanding of the importance of patient-centered care.

Both Sir and Ma'am have gone beyond just teaching; they have mentored me, guiding me in refining my clinical skills and reinforcing the importance of empathy, professionalism, and ethical conduct in medicine. Their unwavering belief in my potential has motivated me to continuously strive for excellence, and I am truly honored to have had the privilege of learning under their expert guidance.

I will always carry with me the lessons they have imparted, and I am immensely thankful for the positive impact they have had on my academic journey and future medical career.

References

[1] World Health Organization. Global Tuberculosis Report 2023. Geneva: WHO; 2023.
Available from: https://www.who.int/publications/i/item/9789240076729

[2] Nicol MP, Workman L, Isaacs W, Munro J, Black F, Eley B, et al. Accuracy of the Xpert MTB/RIF test for the diagnosis of pulmonary tuberculosis in children admitted to hospital in Cape Town, South Africa: a descriptive study. Lancet Infect Dis. 2011;11(11):819–24.

[3] Orikiriza P, Nansumba M, Nyehangane D, Bastard M, Mugisha IT, Nansera D, et al. Xpert MTB/RIF diagnosis of childhood tuberculosis from stool samples in a low-resource setting. Eur Respir J. 2019;54(5):1900400.

[4] Walters E, Demers A-M, van der Zalm MM, Whitelaw A, Palmer M, Bosch C, et al. Molecular detection of Mycobacterium tuberculosis in stool samples for diagnosis of pulmonary tuberculosis in children: A prospective cohort study. Lancet Glob Health. 2021;9(6):e774–83.

[5] Detjen AK, DiNardo AR, Leyden J, Steingart KR, Menzies D, Schiller I, et al. Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis in children: a systematic review and meta-analysis. Lancet Respir Med. 2015;3(6):451–61.

[6] World Health Organization. Rapid Communication: Molecular assays as initial tests for the diagnosis of tuberculosis and rifampicin resistance. Geneva: WHO; 2020.
Available from: https://www.who.int/publications/i/item/9789240000335

[7] Nhu NTQ, Lan NTN, Phuong NT, Chau TTH, Farrar J, Caws M. Evaluation of the Xpert MTB/RIF assay for diagnosis of tuberculous meningitis. J Clin Microbiol. 2014;52(1):226–33.

[8] Lawn SD, Nicol MP. Xpert® MTB/RIF assay: development, evaluation and implementation of a new rapid molecular diagnostic for tuberculosis and rifampicin resistance. Future Microbiol. 2011;6(9):1067–82.

[9] Raghavan, S., & Pradeep, V. (2020). Comparative analysis of tuberculosis control measures in India and China. Journal of Global Health, 10(2), 120-125. https://doi.org/10.7189/jogh.10.020609

[10]                        Lahariya, C. (2023). Social stigma and underreporting in leprosy: A critical challenge for disease elimination. Indian Journal of Leprosy, 95(4), 227-233. https://doi.org/10.2174/0216245000503